- The Current Status of Development of Korean Clinical Practice Guidelines in Urology
-
Yeo JK, Park MG
- KMID: 2448923
- Korean J Urol Oncol.
- 2019 Apr;17(1):1-6.
- doi: 10.22465/kjuo.2019.17.1.1
The clinical practice guidelines (CPGs) is made step by step. The evidences that have been published were searched and a group of experts make a consensus based in the evidences.... -
- CITED
-
- Close
- SHARE
-
- Close
- The Treatment of Metastatic and Castration-Resistant Prostate Cancer Patients in Korea
-
Hah YS, Ha US, Jung JW, Park BH, Kim HJ, Kim KH, Yeo JK
- KMID: 2448927
- Korean J Urol Oncol.
- 2019 Apr;17(1):48-59.
- doi: 10.22465/kjuo.2019.17.1.48
The treatment of advanced prostate cancer has rapidly evolved. Androgen deprivation therapy is recognized as the first-line therapy for metastatic disease; however, a substantial proportion of patients will eventually progress... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment of Patients With High Risk Prostate Cancer
-
Kim JW, Kim KT, Park JY, Yeo J
- KMID: 2448926
- Korean J Urol Oncol.
- 2019 Apr;17(1):34-47.
- doi: 10.22465/kjuo.2019.17.1.34
The Korean Urological Oncology Society has developed a guideline for treatment of prostate cancer by adapting various prostate cancer guidelines in a systematic manner in order to create a guideline... -
- CITED
-
- Close
- SHARE
-
- Close
- The Treatments for Low-Risk Prostate Cancer
-
Lee JW, Jeong JY, Cho IC, Kim SH, Kwon WA, Choi M, Yeo JK
- KMID: 2448924
- Korean J Urol Oncol.
- 2019 Apr;17(1):7-21.
- doi: 10.22465/kjuo.2019.17.1.7
Recently, the prevalence of prostate cancer has been increased with the screening of prostate-specific antigen and the increase in the elderly population. In particular, the diagnosis of the low-risk prostate... -
- CITED
-
- Close
- SHARE
-
- Close
- Primary Leiomyosarcoma in Bladder
-
Kang TW, Eom MS, Chung HC
- KMID: 2448929
- Korean J Urol Oncol.
- 2019 Apr;17(1):66-69.
- doi: 10.22465/kjuo.2019.17.1.66
Leiomyosarcoma of the bladder is a very rare tumor and it has been reported in less than 200 cases in the literature which represent 0.1% of all nonurothelial bladder tumors.... -
- CITED
-
- Close
- SHARE
-
- Close
- Unilateral Multifocal Type 2 Papillary Renal Cell Carcinoma in Adolescence. A Case Report
-
Yoon S, Choi JH, Lee SW, Jeh SU, Hwa JS, Hyun JS, Chung KH, Park HO, Lee JS, Choi SM
- KMID: 2448930
- Korean J Urol Oncol.
- 2019 Apr;17(1):70-73.
- doi: 10.22465/kjuo.2019.17.1.70
Papillary renal cell carcinomas (RCCs) can be classified into 2 subtypes (types 1 and 2), depending on their characteristic cytogenetics, immunostaining profiles, and gene-expression profiles. Compared with type 1 papillary... -
- CITED
-
- Close
- SHARE
-
- Close
- The Treatments for Intermediate Risk Prostate Cancer
-
Shim M, Kwon T, Kim SC, Kim WS, Choo MS, Yeo JK
- KMID: 2448925
- Korean J Urol Oncol.
- 2019 Apr;17(1):22-33.
- doi: 10.22465/kjuo.2019.17.1.22
The population of intermediate-risk prostate cancer patients is a large heterogeneous group with diverse prognoses and challenges the struggle to develop more meticulous and standardized treatment recommendations. Furthermore, there are... -
- CITED
-
- Close
- SHARE
-
- Close
- Serial Comparison of Cancer Detection Rate Between Transrectal Ultrasound Sonography Guided Biopsy and Magnetic Resonance Imaging for Repeat Biopsy by a Propensity Score Matching Cohort: A Single Center Experience
-
Bang S, Choi YH, Kang M, Jeon HG, Jeong BC, Seo SI, Jeon SS, Kim CK, Park BK, Lee HM
- KMID: 2448928
- Korean J Urol Oncol.
- 2019 Apr;17(1):60-65.
- doi: 10.22465/kjuo.2019.17.1.60
PURPOSE: To compare biopsy performance of 2 approaches for multiparametric magnetic resonance imaging (MRI) guided biopsy and transrectal ultrasonography (TRUS)-guided biopsy with 2nd and 3rd repeat biopsy patients in prostate... -
- CITED
-
- Close
- SHARE
-
- Close
